Various presentations of Guillain-Barre syndrome-a case series
DOI:
https://doi.org/10.18203/2349-3291.ijcp20222425Keywords:
GBS, AFP, IvIgGAbstract
Guillain-Barre syndrome (GBS) is a common differential diagnosis for acute flaccid paralysis. It is a notifiable condition in India under acute flaccid paralysis (AFP) surveillance. The presentations can be of varying severity with or without respiratory involvement. Intravenous immunoglobulin (IvIgG) is given to arrest the progression of disease.
References
Gupta D, Nair M, Baheti NN, Sarma PS, Kuruvilla A Diplomate-American Board. Electrodiagnostic and clinical aspects of Guillain-Barré syndrome: an analysis of 142 cases. J Clin Neuromuscul Dis. 2008;10:42-51.
Kannan MA, Ch RK, Jabeen SA, Mridula KR, Rao P, Borgohain R. Clinical, electrophysiological subtypes and antiganglioside antibodies in childhood Guillain-Barré syndrome. Neurol India. 2011;59:727-32.
Berlit P, Rakicky J. The Miller Fisher syndrome. Review of literature. J Clin Neuroophthalm. 1992;12(1):57-63.
Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis. 1997;176(2):S92-8.
Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barre syndrome. N Eng J Med. 1995;333(21):1374-9.
Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr. 2003;142(3):305-9.
Tekgul H, Serdaroglu G, Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain-Barré syndrome in children. Pediatr Neurol. 2003;28(4):295-9.
Shahar E, Leiderman M. Outcome of severe Guillain-Barré syndrome in children: comparison between untreated cases versus gamma-globulin therapy. Clin Neuropharmacol. 2003;26(2):84-7.
Shahar E. Current therapeutic options in severe Guillain-Barré syndrome. Clin Neuropharmacol. 2006;29(1):45-51.
